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The blood–brain barrier (BBB) is a complex physiological checkpoint that restricts the
free diffusion of circulating molecules from the blood into the central nervous system.
Delivering of drugs and other active agents across the BBB is one of the major technical
challenges faced by scientists and medical practitioners. Therefore, development of novel
methodologies to address this challenge holds the key for both the diagnosis and treatment
of brain diseases, such as HIV-associated encephalopathy. Bioconjugated quantum dots
(QDs) are excellent ﬂuorescent probes and nano-vectors, being designed to transverse
across the BBB and visualize drug delivery inside the brain. This paper discusses the
use of functionalized QDs for crossing the blood–brain barrier and treating brain disease.
We highlight the guidelines for using in vitro BBB models for brain disease studies. The
theranostic QDs offers a strategy to signiﬁcantly improve the effective dosages of drugs
to transverse across the BBB and orientate to the targets inside the brain.
Keywords: theranostic quantum dots, HIV-associated encephalopathy, in vitro blood–brain barrier model,
nanomedicine, drug delivery
INTRODUCTION
The blood–brain barrier (BBB) dynamically responds to physio-
logical andpathophysiological events that lead to pathogenesis and
progression of many neurological disorders (Banks, 1999; Banks
et al., 2006). BBBworks as a critical checkpoint between the central
nervous system (CNS) and the peripheral circulation, as Figure 1,
which prevents harmful substances from entering the brain, but
allows the essential nutrients to enter (Schinkel, 1999). The trans-
porters that help the uptake by the BBB include GLUT-1, a glucose
carrier, and L1, an amino acid transporter, while the BBB reject
foreign substances by an efﬂux mechanisms that uses efﬂux trans-
porters such as P-glycoprotein (Fromm, 2000; Sun et al., 2003).
However, this barrier also blocks therapeutic drugs to reach the
pathological tissues behind BBB (Abbott, 2002; Abbott et al., 2010;
Abbott and Friedman, 2012). Since the BBB limits the brain pene-
tration of most CNS drug candidates, neurological disorders such
as HIV-associated encephalopathy (HIVE), has signiﬁcant mor-
bidity andmortality (Berger and Avison, 2004; Alexaki et al., 2008;
Strazza et al., 2011).
The BBB is a dynamic interface that controls the inﬂux and
efﬂux of a wide variety of substances, including endogenous
nutrients and exogenous compounds such as drugs, therebymain-
taining a homeostatic environment for the CNS (Ballabh et al.,
2004; Weiss et al., 2009). Under normal physiological conditions,
BBB prevents transport of bacteria, large molecules, and most
small molecules into the brain. To be BBB permeable, molecules
need to be lipid soluble, and less than 400 Da in size. Larger
biomolecules, which are unable to cross the BBB due to their
size and polarity, could pass through the BBB if they are trans-
ported by receptor-mediated transcytosis (RMT) using ligands
that bind to speciﬁc BBB receptors. There are more than 7000
drugs in the comprehensive medicinal chemistry database, and
only 5% of these drugs can be used to treat the CNS diseases,
with the most predominant being for the treatment of depression,
schizophrenia, and insomnia (Ghose et al., 1999). In a related
study, 12% of all drugs are shown to be active in the CNS, but
only 1% of all drugs are active in the brain for diseases other
than affective disorders (Lipinski, 2000). The importance of devel-
oping new approaches to brain drug development is illustrated
by considering the limitations of the existing brain drug deliv-
ery strategies. These delivery systems include transcranial brain
drug delivery, trans-nasal brain drug delivery, BBB disruption,
and small molecule lipidization (Pardridge, 2012; Pardridge and
Boado, 2012). Alternatively, lipid carriers are attached to water-
soluble drugs. However, in actual practice, the reformulation of
a water soluble drug with lipidization modiﬁcations is difﬁcult to
execute successfully. Currently, there is not a single example of a
drug presently sold whereby medicinal chemistry was successfully
used to convert non-brain-penetrating drug into a molecule that
crosses the BBB in pharmacologically signiﬁcant amounts.
Fortunately, nanotechnology offer great promise for overcom-
ing the limited penetration of drugs through the BBB (Jain, 2012).
Over the last two decades, nanoparticle research has focused on the
development of new drug delivery vehicles (Bruchez et al., 1998;
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FIGURE 1 | Anatomical structure of the blood–brain barrier. (A)The diagram of blood–brain barrier in vivo. (B) Magniﬁcation of the BBB. The brain
endothelium forms the BBB.
Ghose et al., 1999; Prasad, 2004). New nanomaterials, includ-
ing QDs, gold nanoparticles, carbon nanotubes, ultra-sensitive
nanosensors, smart nanomaterials, molecular motors, shape
memory nanomaterials, and biological templates for nanoscale
devices, had been investigated in nanomedicine (Kubitschko et al.,
1997; Titus and Gilbert, 1999). It is known that the numer-
ous drugs, though being highly efﬁcacious, are limited in their
therapeutic applications owing to their poor solubility and sta-
bility in physiological medium (Davis, 1997). Nanoparticles not
only enable the development of stable aqueous formulation of
such drugs, but also help in their bioavailability and site-speciﬁc
delivery, using biotargeting approaches (Uhrich et al., 1999). In
addition, nanoparticles also can be designed for the sustained or
externally controlled release of these drugs from theparticlematrix
within the target site of interest (Kreuter, 2004). Furthermore,
these enhanced drug-delivery nanoplatforms can be combined
with diagnostic probes, as well as designed to target “hard-to-
reach” diseased sites. For example, the transferrin (Tf) is a type of
Fe-binding glycoprotein and they could be easily used to conjugate
with nanoparticles for targeting the BBB and facilitate the RMT
process. Tf receptor (TfR) mediates cellular uptake of iron bound
to Tf. Upon binding of Tf to its receptor, the receptor-ligand com-
plex is endocytosed via clathrin-coated vesicles and occurs in 3
steps (1) receptor-mediated endocytosis of the compound at the
luminal (blood) side, (2) movement through the endothelial cyto-
plasm, and (3) exocytosis at the abluminal (brain) side of the brain
capillary endothelium. These multimodal nanoparticles would
be ideal candidates for curing such diseases which are currently
untreatable using standard chemo/radio-therapeutic and surgical
approaches.
Though a number of approaches have been used for deliv-
ery of liposomes containing drugs and genes across the BBB in
small animals, only handful of reports of nanoparticle delivery
using immunotargeting approach can be found in the literature
(Pardridge, 2012; Pardridge and Boado, 2012). Thus, there is
a great interest in the nanomedicine ﬁeld to develop optimized
traceable drug-loaded nanoparticle formulations that can be safely
used to facilitate drugs across the BBB for treating the brain dis-
eases, and at the same time visualize the distribution proﬁle of
the nanoparticles in the brain. Therefore, in this review, the
development of functionalized ﬂuorescent QDs for crossing the
blood–brain barrier and treating brain disease will be discussed
and presented. The guidelines for using in vitro BBB models for
brain disease studies will be highlighted. This review is intended
to discuss the current developments of QD bioconjugates for
transmigration across BBB and therapy of brain diseases.
QUANTUM DOTS IN NANOMEDICINE APPLICATIONS
Quantum dots are semiconductor nanocrystals that have sizes
ranging from 2 to 10 nm. In general, it is well documented that
the emission wavelength of the QDs can be tuned from 450 to
1800 nm by manipulating their size, shape, and composition of
the nanocrystals. QDs possess a few unique optical properties. For
example, they have excellent resistance to photo-bleaching, large
absorption cross section, relatively long ﬂuorescence lifetime, and
good quantum yield that can be as large as 70–80% (Yong et al.,
2009b). The narrow emission and broad excitation spectra make
it possible to trace the dynamics of several interested molecules
in vivo or in vitro (Gao et al., 2005). In addition, the large two
photon absorption cross section of QDs, compared to organic
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dyes, makes them very promising optical agents for two-photon
laser excitation, which can be performed in the near-infrared win-
dow with better imaging penetration depth in tissue (Hilderbrand
and Weissleder, 2010; Yong et al., 2011). These properties make
QDs very attractive for biophotonics and nanomedicine research
applications.
To date, colloidal core/shell QDs such as CdSe/ZnS,
CdSe/ZnCdS, CdTe/CdSe, and InP/ZnS are being commonly
used in biological and medical research (Michalet et al., 2005;
Pinaud et al., 2010). Among many methods available in the lit-
erature for synthesizing QDs, hot colloidal synthesis approach
remains the most promising approach for obtaining robust QDs
for nanomedicine applications. For core QDs such as CdSe and
CdTe, they can be prepared at high temperature by the reaction
between cadmium oxide dissolved in oleic acid and trioctylphos-
phine (TOP) and/or TOP-Selenium. The reaction resulted in the
formation of mono-dispersed QDs. However, synthesized QDs
are unable to be employed in biological applications unless the
following critical challenges are addressed (Figure 2).
First, it is important to passivate the coreQDwith a thin layer of
high band gap materials, such as ZnS. There are many advantages
for core/shell QDs upon comparing with unpassivated ones. For
example, it was discovered that the chemical and optical stabili-
ties of QDs can be maintained when the QDs are passivated with
higher band-gap semiconductormaterials. Also, the shells will sig-
niﬁcantly reduce theQDs toxicity,whichmakes themamenable for
biological applications (Hedi et al., 2000). Although many types
of core/shell QDs were fabricated, only CdSe/ZnS, CdTe/ZnS, and
CdSe/CdS/ZnS were found to be useful for in vivo imaging appli-
cations. However, there does exist toxicity concerns about CdSe
and CdTe QDs due to the presence of cadmium, and further stud-
ies are needed to resolve these challenges. In recent years, many
research teams have prepared cadmium-free QDs such as InP,
CuInS2,AgInS2, and silicon for biological applications (Erogbogbo
et al., 2008; Yong et al., 2009a, 2010; Liu et al., 2013).
Second, general high quality core/shell QDs are prepared by
using hot colloidal synthesis and its surface is passivated with
hydrophobic moieties, which prohibit them to be dispersible
in aqueous phase. Thus, water-dispersible QDs with reactive
functional groups are needed for in vitro and in vivo applications.
The techniques for transferring organically dispersible core/shell
QDs from organic phase to aqueous phase have been extensively
studied for the last decade. In general, the approaches used for
fabricating water-dispersible QDs includes (i) functionalizing QD
surface with amphiphilic molecules such as mercapto acids, and
hydrophilic dendrimers; and (ii) coating the QDs with biocom-
patible surface layer such silica-shell and amphiphilic polymers.
For example, Chan et al. demonstrated the preparation of water
dispersible CdSe/ZnS QDs for in vitro imaging by functionalizing
the QD surface with mercaptoacetic acid through ligand exchange
method (Bruchez et al., 1998; Chan and Nie, 1998). Using a sim-
ilar approach, Uyeda et al. demonstrated that water-dispersible
QDs can be prepared by functionalizing the QD surface with the
bidentate dihydrolipoic acid (DHLA) (Uyeda et al., 2005). To date,
surfacemodiﬁcation of QDs usingmercapto ligands has remained
a popular method for preparing water dispersible QDs (Medintz
et al., 2005).
Third, conjugation of biomolecules to the surface of water-
dispersible QDs is another important requirement for in vitro and
in vivo targeted delivery applications. Biomolecules such as anti-
bodies, nucleic acids, peptides, and aptamers can be attached to
the QD surface by either covalent or non-covalent interactions.
Commonly, conjugation of proteins, antibodies, peptides, and
drug molecules to the QD surface is required for targeted deliv-
ery to the area of interest. The QD surface can be decorated with
functional groups such as carboxylic acid, primary amine, and
thiol, which can be used for conjugation with targeting ligands by
using conjugation chemistries such as carbodiimide, maleimide,
and succinimide. Avidin-biotin cross-linking technique is another
popular method for conjugating biomolecules on the surface of
QDs.
QUANTUM DOTS IN HIV-ASSOCIATED ENCEPHALOPATHY
THERAPY
IN VITRO MODELS OF THE HUMAN BBB
The BBB is a critical interface and acts as a physical and metabolic
barrier between the CNS and the peripheral circulation that serves
to regulate and protect the microenvironment of the brain. The
FIGURE 2 | Functionalized QDs and its theranostic mechanism at cellular level. (A)Theranostic QDs. (B)The dynamics of QDs-based nanoplex inside living
cells.
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primary function of the normal BBB is to establish and maintain
homeostasis in the CNS (Bradbury, 1993; Abbott and Friedman,
2012). The BBB is not rigid and comprises of dynamic vessels that
are capable of responding to rapid changes in the brain or blood.
It is composed of specialized brain capillary endothelial cells (e.g.,
BMVECs) and astrocytic end-feet that enhance the differentiation
of BBB endothelium (Abbott, 2002; Abbott et al., 2010; Abbott
and Friedman, 2012). The BBB has at least three types of cell-to-
cell junction structures between adjacent endothelial cells and/or
astrocytes, which are the gap junctions, adherens junction, and the
tight junctions. The high expression of tight junction proteins is
a special characteristic of the BBB (de Lange, 2012; Luissint et al.,
2012).
Animal experiments for drug screening of brain disease are
time-consuming and costly, which seriously impedes the brain
drug development. There is a considerable interest in establishing
in vitro BBB cell culture models for a few reasons such as studying
drugs that penetrate the BBB and understanding how abnormality
of the BBB is correlatedwith the pathogenesis of various neurolog-
ical diseases (Stanness et al.,1996). Agood in vitroBBBmodelmust
reproduce the salient features of the in vivo BBB and also allow
one to manipulate the system to mimic the neuropathogenic pro-
cess. Fortunately, several in vitro tissue culture systems have been
developed to reproduce the physical and biochemical properties
of the intact BBB (Stanness et al., 1999; Cucullo et al., 2002, 2005;
Santaguida et al., 2006; Naik and Cucullo, 2012). Many groups
have employed a setup using a porous membrane support as sub-
strate for culturing BMVEC in vitro that is submerged in culture
media (Figure 3A). This system is characterized by side-to-side
diffusion, is capable of inducing polarity in the endothelial cells
and permits study of bidirectional transendothelial transport of
solutes (Joo, 1993).
A major disadvantage of this system is the lack of physiologic
shear stress that induces tight junction qualities in BMVEC.There-
fore, it is generally reported that the tightness of the barrier in this
FIGURE 3 |The development of in vitro BBB model. (A) Monolayer in
vitro BBB. (B) Bilayer in vitro BBB.
type of model is much less stringent than that of the in vivo BBB.
A dynamic, three dimensional in vitro culture system (DIV-BBB)
is more relevant to the in vivo BBB phenotype than other models
(Cucullo et al., 2011; Naik and Cucullo, 2012). In this model, the
endothelial cells are cultured with astrocytes across a membrane
with pore size of 0.1–0.5 μm, under pulsate ﬂow (Figure 3B). In
general, this model is not suitable for examining the transmigra-
tion process because of the extremely small size of the membrane
pores. The advantages of this model are the presence of sheer
stress, easier regulation of nutrients and gases, and closest model
mimicking the in vivo BBB. The co-culture model has been exten-
sively used to date because it can be conveniently and reproducibly
formed in large quantities. More importantly, the system provides
detailed information about the cellular andmolecularmechanisms
of a wide variety of neurological disease conditions. The use of
astrocyte co-culture and conditionedmedia have been reported to
reduce the permeability of the BMVEC (Rubin et al., 1991). Astro-
cytes also may inﬂuence the expression of adhesion molecules by
the BMVEC that form the BBB. The Persidsky model uses a 3.0-
μm diameter polyethylene terephthalate (PET) membrane insert,
while other investigators use a 0.45-μm diameter PET membrane
insert (Persidsky et al., 1997; Mukhtar and Pomerantz, 2000).
In our study, we have validated the transwell co-culture model
that provides an opportunity to examine the expression of tight
junction protein, permeability, and transmigration of different
leukocyte populations under different experimental stimuli. Thus,
we propose that, although somemodel systemsmay be better than
others, the most important aspect of any study is the accuracy and
reproducibility of the model and its ability to allowmanipulations
in mimicking disease processes.
GENE SILENCING USING QD/SIRNA NANOPLEX DELIVERY TO
MAINTAIN THE INTEGRITY OF THE BLOOD–BRAIN BARRIER
In neuroinﬂammatory conditions, such as multiple sclerosis,
HIVE, meningitis, cerebral ischemia, and brain tumors, the
matrix-degrading metalloproteinases (MMP) play an important
role in disrupting the BBB.MMPs are proteolytic enzymes that are
instrumental in the turnover of the extracellular matrix (ECM),
and are mediators of cell migration. MMP-9 is known to mediate
the transmigration of inﬂammatory leukocytes across basement
membranes, thus leading to proteolytic degradation of ECM
components. In addition to degrading the neurovascular matrix,
MMP-9 promotes neuronal apoptosis by disrupting cell-matrix
interactions that enhance the permeability of the BBB, thereby
exacerbating neurological diseases such as HIVE (Erickson et al.,
2012). In vitro studies employed brain endothelial cell cultures
activated with the pro-inﬂammatory cytokines, tumor necrosis
factor-alpha (TNF-α), and interleukin-1beta (IL-1β), caused selec-
tive up-regulation of MMP-9 activity, but no signiﬁcant changes
were observed in the MMP-2 or TIMP-2 levels. This proves that
MMP-9 is a predominant MMP in neuroinﬂammatory processes
that leads to BBB leakage and disruption.
The inhibition of MMP-9 activity using delivery of short inter-
fering RNA (siRNA) molecules at BMVECs will have a major
impact on lowering the BBB permeability. However, a major
limitation of this approach is to safely and efﬁciently deliver
siRNA molecules to their target. In addition, free form of siRNA
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molecules has a very short half-life in physiological conditions
that is due to their vulnerability for degradation through endoge-
nous nucleases process. Therefore, they need to be integrated with
nanoparticle that will not only protect them from degradation
in the biological environment, but also able to direct them to
targeted cells or tissues and subsequently facilitate their cellular
entry.
In a recent study, we have evaluated the speciﬁcity and efﬁ-
ciency of QD complexed with MMP-9-siRNA (nanoplex) in
down-regulating the expression of MMP-9 gene in BMVEC that
constitute the BBB (Bonoiu et al., 2009). Our results show that
silencing of MMP-9 gene expression resulted in the up-regulation
of ECMproteins like collagen I, IV,V, and a decrease in endothelial
permeability, as reﬂected by increase of transendothelial resistance
(TEER) across the BBB in a well validated in vitro BBB model.
MMP-9 gene silencing also resulted in an increase in expression
of the gene tissue inhibitor of metalloproteinase-1 (TIMP-1). This
indicates the importance of a balance between the levels of MMP-
9 and its natural inhibitor TIMP-1 in maintaining the basement
membrane integrity. These studies promise the application of a
novel QD based siRNA delivery system in modulating the MMP-
9 activity in BMVECs and other MMP-9 producing cells. This
strategy will serve as a platform to design clinically useful QD
formulation for preventing neuroinﬂammation and maintain the
integrity of the BBB.
TRANSCYTOSIS OF BIOCONJUGATED QUANTUM DOTS THROUGH THE
IN VITRO MODEL OF BBB
Recently, we have demonstrated the use of QD bioconjugates
as efﬁcient targeted probes for transmigration across the BBB
(Bharali et al., 2005; Lucey et al., 2005; Qian et al., 2007). A val-
idated endothelial and astrocytic co-culture BBB model was used
to determine the transmigration of QD bioconjugates across the
BBB. Since the transferrin receptor protein is highly localized on
the endothelial surface of the brain, transferrin was selected to
trigger receptor-mediated transport across theBBB.Tf-conjugated
QD formulation was prepared and employed for migrating across
the in vitro BBB model via receptor-mediated transport mech-
anism (Xu et al., 2008). It was discovered that the migration
rate of Tf-conjugated QDs crossing the in vitro BBB is both
concentration- and time-dependent (Figure 4). In our study, fol-
lowing overnight incubation of the Tf-QD bioconjugates with
media in the upper chamber of the BBB, the BBB permeability
was assayed by quantifying the ﬂuorescence intensity of the media
in the upper and the lower chamber of the model, using confocal
imaging of both the upper and lower sides of the PET membrane.
From the QD ﬂuorescence observed from the lower media, one
can see that a portion of the QD-Tf bioconjugates has traversed
across the BBB,which is not the case for the control, unconjugated
QDs. In addition, confocal microscopic analysis has revealed QD
staining on both the upper and lower sides of the PET membrane
following treatment with Tf-QD bioconjugates, providing strong
evidence for the successful traversing of the functionalized QDs.
In the case of treatment with the unconjugated QDs, on the other
hand, the QD staining is only observed in the upper side (mim-
icking the “blood”-end), and not in the lower side (mimicking
the “brain”-end), of the PET membrane. These studies provide
support that QDs can be directed to cross the blood–brain barrier
using our in vitro model.
In addition, tight-junction protein Claudin-4 was used con-
currently to validate the multiplex imaging technique and also to
evaluate quasi-quantitatively the comparative transmigration efﬁ-
ciency and speciﬁcity of Tf and anti-Claudin 4 antibody (aC4),
by conjugating them with red and orange emitting QDs, respec-
tively. The results showed higher transmigration efﬁciency of
Tf-conjugated QDs over the aC4-conjugated ones across the BBB.
This work shows for the ﬁrst time that the QD multiplexing
technique is employed to compare the targeting efﬁciency of dif-
ferent speciﬁc molecules across the BBB. These results illustrate a
QD-based platform that will not only allow a direct visualization
and quantiﬁcation of the transmigration ability of various kinds
of biomolecules across the BBB,but also facilitate the development
FIGURE 4 |Visulizing the trancytosisi of QDs-Tf across BBB real-time.The endothelial cells and astrocytes were imaged by laser scanning confocal
microscope to conﬁrm the uptake of QDs by both cells. The ﬂuorescent intensity of the culture media were collected and detected to evaluate the
transmigration of QDs.
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of novel diagnostic and therapeutic nanoprobes for early diagnosis
and therapy of various disorders of the brain following systemic
administration.
QDs ENHANCING THE DELIVERY OF ANTIRETROVIRAL DRUGS ACROSS
THE IN VITRO MODEL OF HIVE
Highly active antiretroviral therapy (HAART) drugs applied for
HIV-infected therapy has signiﬁcantly improved the prognosis of
patients. However, the antiretroviral drugs cannot eradicate the
HIV virus in the brain because of their poor permeability across
the BBB. Consequently, HIV virus in the brain continue to repli-
cate and the HIVE process keep on augmenting, even when the
level of HIV-1 virus is too low to be detectable in the peripheral
blood. Generally, the HIVE was treated by exposing the whole
body to multiple drugs at high doses, resulting in enormous side
effects, including the multi-drug resistance. Thus, development
of targeted approaches or increasing the drug-delivery efﬁciency
will improve the safety and efﬁcacy of HAART by reducing the
dosage and adverse effects. Thus, the theranostic QDs have been
prepared by conjugating the ﬂuorescent QDs with the targeting
molecule transferrin and theHAARTdrug Saquinavir, which is the
ﬁrst protease inhibitor approved by the Food and Drug Admin-
istration (FAD) of United States (Mahajan et al., 2010). In order
to shorten the experimental cycle and reduce the cost, a HIVE
in vitro model has been established. Besides the BBB in vitro
model as in Section “Transcytosis of Bioconjugated QDs Through
the IN VITRO Model Of BBB,” HIV-1 infected peripheral blood
mononuclear cells (PBMCs) are cultured on the bottom of the
lower chamber (basolateral end), as Figure 5. The concentration
of Saquinavir used in this work was 10 and 40 nM, within the
effective concentration range of this drug.
The results demonstrated the nanoplex did not change the
integrity of the BBB in HIVE in vitro model, as assessed by
the TEER value during transversing across the BBB. Signiﬁcant
decrease in p24 production and LTR/RU5 gene expression in
the HIV-1 infected PBMCs was observed, which veriﬁed that
the antiviral efﬁcacy of Saquinavir was enhanced when delivered
by the targeted nanocarrier across the BBB. Our results demon-
strated that theQDs-Tf-Saquinavir nanoformulation increases the
drug solubility, enhance systemic bioavailability, and the excellent
optical properties of QDs also visualizes the distribution and accu-
mulation of nanoplexes in brain. In another previous work, we
used the same strategy to construct a novel theranostic nanofor-
mulation by conjugating HAART drug Amprenavir, QDs, and Tf.
The p24 production and LTR/RU5 gene expression in the HIV-
1 infected PBMCs were decreased signiﬁcantly as well (Mahajan
et al., 2012).
Both the studies mentioned above demonstrated that the QDs-
Tf-HAART drugs nanoformulation can transverse the BBB and
signiﬁcantly inhibit HIV-1 replication in the infected PBMCs.
Such primary results offered the basis to develop novel QD based
nanoplex with targeting molecules and HAART drugs, which
could enhance the drug delivery efﬁcacy across the BBB and facil-
itate the uptake of the nanoplex by HIV-1 infected cells in the
brain.
The application of nanotechnology provides unprecedented
opportunities for addressingmany of the gaps in the diagnosis and
therapy of diseases. Nanoparticle technology offers a signiﬁcant
advancement in the ability to increase drug translocation across
the BBB. The development of BBB permeable, multifunctional
drug-loaded nanoparticles will provide a signiﬁcant advance-
ment toward the therapy of neurological disorders associated with
HIV-1; further, these nanoparticle systems will integrate high-
resolution imaging capability in addition to therapeutic modal-
ities. We have demonstrated the ability of a Tf-QD-Amprenavir
nanoplex to transverse the BBB and signiﬁcantly inhibit HIV-
1 replication in HIV-1-infected monocytes, demonstrating their
anti-HIV-1 efﬁcacy in the brain. The use of such nanotechnology
FIGURE 5 |The therapy of QDs-based nanoplex for in vitro HIV-associated encephalopathy model.
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platforms for delivery of antiretroviral drugs will revolutionize the
treatment of neuro-AIDS.
SUMMARY AND FUTURE OUTLOOK
This review discusses the potential use of QD bioconjugates
for sneaking of drugs and/or imaging agents across the BBB,
that would allow simultaneous imaging and therapy in targeted
areas of the brain. The successfully engineered transmigra-
tional QDs in vivo would allow groundbreaking technological
advances in functional imaging and therapeutic approaches for
the diagnosis and treatment of several brain diseases such as
brain tumor, stroke, neuro-AIDS, and neurodegenerative dis-
orders. The BBB is one of the major physiological “conun-
drums,” which on one hand prevents the brain from damage
by unwanted blood-borne pathogens and toxins, whereas on
the other hand impedes the systemic delivery of diagnostic
and therapeutic agents in the CNS. In addition to signiﬁcantly
advancing the diagnosis and therapeutic technologies within
the CNS, this review also highlights the basic scientiﬁc mecha-
nism of transport across the BBB, which would provide useful
guidelines for other researchers to bolster the drug discovery
program aimed at CNS therapeutics. This QD technology for
migrating across BBB could potentially transform into person-
alized medicine. The translational impact of this technology
lies in the drug delivery across the BBB and further engi-
neered QD formulations integrated with therapeutic drugs and
molecules for tissue speciﬁc recognition and sustained release
of the therapeutic drug from the nanoparticles once it reaches
its target tissue. In the long term, this developed technol-
ogy will be generalized toward the development of advanced
diagnostic/therapeutic strategies for treating neurological disor-
ders.
Despite the encouraging result on using QDs for drug delivery
across the BBB, there remains a serious concern about the toxic-
ity of the QDs in vivo that is mainly originated from the intrinsic
potential toxic nature of the semiconductor materials themselves
(Won et al., 2009). To date, different strategies have been created
to reduce the toxicity and side effects of QDs, including coat-
ing the QDs with biocompatible polymer and synthesizing the
cadmium-free QDs that is based on silicon or carbon materials
(Hardman, 2006; Erogbogbo et al., 2008). We believe that these
proposed strategies will allow one to fabricate QDs with mini-
mum toxicity and employ them for neurological pharmaceutical
applications.
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